Table 1.

Summary of currently approved jakinibs, including JAK selectivity and indications.

JAK Inhibitor	Target	Indication	References
tofacitinib	JAK1, JAK3	RA, PsA, UC, adult and juvenile PsA (patients > 2)	[23]
	JAK2	juvenile idiopathic arthritis (patients > 2 years old)
ruxolitinib	JAK1	PV, intermediate-high myelofibrosis, SR-GVHD	[22,24]
	JAK2	AD (topical cream)
baricitinib	JAK1	RA 1, AD 2	[25,26]
	JAK2	COVID-19 3
upadacitinib	JAK1	RA, PsA, AS 4, moderate-severe AD 4	[27,28]
filgotinib	JAK1	RA 4, UC 2	[29]
abrocitinib	JAK1	AD 5	[30]
fedratinib	JAK2	intermediate-high risk	[31]
	FLT3	primary or secondary myelofibrosis
peficitinib	pan-JAK	RA 6	[32]
delgocitinib	pan-JAK	AD 7	[33]
ocalacitinib	JAK1, JAK2	canine allergic dermatitis	[34]
	JAK3

RA: rheumatoid arthritis, PsA: psoriatic arthritis, UC: ulcerative colitis, PV: polycythemia vera, SR-GVHD: steroid refractory-graft-versus-host-disease, AD: atopic dermatitis, AS: ankylosing spondyloarthritis. ¹ 2 mg and 4 mg doses approved by the European Medicines Agency (EMA), only the 4 mg dose approved by the Food and Drug Administration (FDA). ² Approved by the EMA, not approved by the FDA. ³ FDA Emergency Use Authorization for 4 mg baricitinib monotherapy and baricitinib in combination with remdesivir for treatment of hospitalized-COVID-19 patients over 2 years old requiring supplemental oxygen, ventilation or extracorporeal membrane oxygenation. ⁴ Approved by the EMA, not yet approved by the FDA. ⁵ Approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency to treat severe AD in adults and adolescents 12 years and up, also granted FDA Priority Review and is Recommended for EMA Approval. ⁶ Approved in South Korea and Japan only. ⁷ Approved by the Japanese Pharmaceutical and Medical Devices Agency.